国产精品丝袜久久久久久消防器材,国产美女激情视频,国产精品白丝久久av网站

Global Biopharma Layoffs March 2026 Layoffs Global Biopharma companies including Merck, Baye, and Novartis announce workforce reductions in March 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Global Biopharma Layoffs November 2025 Layoffs This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Bayer $1.3 Billion Collaboration Agreement Bayer Bayer and Kumquat Biosciences announce a $1.3 billion global collaboration to develop and commercialize a KRAS G12D inhibitor, aiming to offer new treatment options for pancreatic, colorectal, and lung cancer patients.
Global Biopharma Layoffs August 2025 Layoffs The biopharmaceutical industry sees major August layoffs, with companies like Moderna, Merck cutting jobs amid restructurings, trial setbacks, and M&A activity.
Bayer’s Nubeqa Gains FDA Expansion for Broader Prostate Cancer Use Bayer Bayer secures FDA approval to expand Nubeqa's use for all metastatic castration-sensitive prostate cancer patients, including those unable to tolerate chemotherapy, strengthening its position in the prostate cancer treatment market.
Vividion Gains Rights to Covalent WRN Inhibitor VVD-214 from Roche Bayer Bayer’s Vividion Therapeutics secures exclusive global rights to VVD-214, the only clinical-stage covalent WRN inhibitor, from Roche. The drug shows early promise for treating MSI-high cancers in phase 1 trials.
Nuclear Medicine Titans: The Battle in a $10 Billion Market Bayer Explore how pharma giants like Novartis, Bayer, AstraZeneca, BMS, and Eli Lilly are battling for dominance in the booming $10B radiopharmaceutical market with cutting-edge therapies and strategic acquisitions.
Bayer's 2024 Financial report Financial statements Bayer's 2024 financial report reveals a 2.2% revenue decline, 6,908 job cuts, and ongoing legal battles. With strategic shifts and heavy R&D investment, the company faces challenges and opportunities ahead. Can Bayer turn the tide by 2025?
MNC Profiles: Who Values ??the Chinese Market Most? AstraZeneca Explore the competitive landscape of multinational pharmaceutical companies (MNCs) in China’s booming healthcare market. Delves into MNC revenue trends, strategies, and insights, highlighting which companies value the Chinese market most.
African smallholder farmers push for better tech access in regenerative agriculture. Bayer African smallholder farmers are calling for policy reforms to improve access to technology for regenerative agriculture. At a Rome roundtable, they highlighted the need for outcome-driven, technology-neutral solutions to boost productivity, resilience, sustainability in the face of climate change.

<Pre12 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a